Extramedullary vs medullary relapse after autologous or allogeneic hematopoietic stem cell transplantation (HSCT) in multiple myeloma (MM) and its correlation to clinical outcome

Bone Marrow Transplantation

Volumn 34, Issue 12, 2004, Pages 1057-1065

  Zeiser, R ^a   Deschler, B ^a   Bertz, H ^a   Finke, J ^a   Engelhardt, M ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Donor lymphocyte infusion (DLI); Extramedullary plasmocytoma; Hematopoietic stem cell transplantation (HSCT); Multiple myeloma (MM)

Indexed keywords

ALPHA INTERFERON; BETA 2 MICROGLOBULIN; BUSULFAN; CARMUSTINE; CORTICOSTEROID DERIVATIVE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; DEXAMETHASONE; EPIRUBICIN; ETOPOSIDE; FLUDARABINE; IFOSFAMIDE; MELPHALAN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THALIDOMIDE; THIOTEPA; THYMOCYTE ANTIBODY;

ADULT; AGE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLOOD DONOR; BONE DISEASE; CANCER RELAPSE; CENTRAL NERVOUS SYSTEM DISEASE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOGENETICS; DRUG FATALITY; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HUMAN; INTERMETHOD COMPARISON; LUNG DISEASE; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PERICARDIAL DISEASE; PRIORITY JOURNAL; RISK ASSESSMENT; SKIN DISEASE; SOFT TISSUE DISEASE; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; TREATMENT OUTCOME; WHOLE BODY RADIATION;

ADULT; BONE MARROW; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOCYTE TRANSFUSION; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; RECURRENCE; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 11144314915     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704713     Document Type: Article

References (41)

1. Child JA, Morgan GJ, Davies FE et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875-1883.
2. Attal M, Harousseau JL, Facon T et al. Single vs double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003; 349: 2495-2502.
3. Bensinger WI, Rowley SD, Demirer T et al. High-dose therapy followed by autologous hematopoietic stem-cell infusion for patients with multiple myeloma. J Clin Oncol 1996; 14: 1447-1453.
4. Barlogie B, Jagannath S, Vesole DH et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 1997; 89: 789-795.
5. Bensinger WI, Buckner CD, Anasetti C et al. Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome. Blood 1996; 88: 2787-2792.
6. Gahrton G, Tura S, Ljungman P et al. Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma. J Clin Oncol 1995; 13: 1312-1317.
7. Rosler W, Strobel G, Sendler A et al. Relapse of light-chain myeloma after allogeneic bone marrow transplantation: no recurrence of myeloma protein. Bone Marrow Transplant 1996; 17 71 (abstr. 329).
8. Zomas A, Stefanoudaki K, Fisfis M et al. Graft-versus-myeloma after donor leukocyte infusion: maintenance of marrow remission but extramedullary relapse with plasmocytomas. Bone Marrow Transplant 1998; 21: 1163-1165.
9. Umeno Y, Kogawa K, Matsuishi E et al. A case of multiple myeloma which developed into multiple extramedullary involvement in the terminal stage. Fukuoka Igaku Zasshi 2000; 91: 55-61.
10. Richardson PG, Barlogie B, Berenson J et al. A phase II study of bortezomib in relapsed and refractory myeloma. N Engl J Med 2003; 348: 2609-2617.
11. Metha J. The graft-versus-myeloma effect. In: Barrett AJ, Jiang YZ (eds). The Graft-Versus-Leukemia Effect in Allogeneic Stem Cell Transplantation. Marcel-Dekker: New York, 1998.
12. Aleya EP, Schlossman RL, Canning C et al. CD8-depleted donor lymphocyte infusions mediate graft-versus-multiple-myeloma (MM) effect. Blood 1996; 87: 258a (abstr. 1021).
13. van der Griend R, Verdonck LF, Veenbuizen P et al. Donor leukocyte infusions inducing remissions repeatedly in a patient with recurrent multiple myeloma after allogeneic bone marrow transplantation. Bone Marrow Transplant 1999; 23: 195-197.
14. Gore ME, Selby PJ, Viner C et al. Intensive treatment of multiple myeloma and criteria for complete remission. Lancet 1989; 2: 879-883.
15. Blade J, Samson D, Reece D et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose chemotherapy and haematopoietic stem cell transplantation. Meyloma Subcommittee of the EBMT. European Group of Blood and Marrow Transplantation. Br J Haematol 1998; 102: 1115-1123.
16. Goldschmidt H, Hegenbart U, Wallmeier M et al. High-dose therapy with peripheral blood progenitor cell transplantation in multiple myeloma. Ann Oncol 1997; 8: 243-246.
17. Neidhart JA, Kohler W, Stidley C et al. Phase I study of repeated cycles of high-dose cyclophosphamide, etoposide, and cisplatin administered without bone marrow transplantation. J Clin Oncol 1990; 8: 1728-1738.
18. Johnson RJ, Owen RG, Smith GM et al. Peripheral blood stem cell transplantation in myeloma using CD34 selected cells. Bone Marrow Transplant 1996; 17: 723-727.
19. Finke J, Brugger W, Bertz H et al. Allogeneic transplantation of positively selected peripheral blood CD34+ progenitor cells from matched related donors. Bone Marrow Transplant 1996; 18: 1081-1086.
20. 2). Leukemia 2004; 18: 133-138.
21. Mills W, Chopra R, McMillan A et al. BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol 1995; 13: 588-595.
22. Wäsch R, Reisser S, Hahn J et al. Rapid achievement of complete donor chimerism and low regimen-related toxicity after reduced conditioning with fludarabine, carmustine, melphalan and allogencic transplantation. Bone Marrow Transplant 2000; 26: 243-250.
23. Bertz H, Potthoff K, Mertelsmann R et al. Busulfan/cyclophospamide in volunteer unrelated donor (VUD) BMT: excellent feasibility and low incidence of treatment-related toxicity. Bone Marrow Transplant 1997; 19: 1169-1175.
24. Finke J, Bertz H, Schmoor C et al. Allogeneic bone marrow transplantation from unrelated donors using in vivo anti-T-cell globulin. Br J Haematol 2000; 111: 303-313.
25. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
26. Mantel N. Evaluation of survival data and two new rank order statistics arising in ist consideration. Cancer Chemother Rep 1966; 50: 163-170.
27. Alexanian R, Haut A, Khan AU et al. Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. JAMA 1969; 208: 1680-1685.
28. Alexanian R, Dimopoulos MA, Delasalle K et al. Primary dexamethasone treatment of multiple myeloma. Blood 1992; 80: 887-890.
29. Bjorkstrand B, Ljunman P, Bird JM et al. Autologous stem cell transplantation in multiple myeloma: results of the European Group for Bone Marrow Transplantation. Stem Cells 1995; 13: 140-146.
30. Singhal S, Powles R, Sirohi B et al. Response to induction chemotherapy is not essential to obtain survival benefit from high-dose melphalan and autotransplantation in myeloma. Bone Marrow Transplant 2002; 30: 673-679.
31. Lokhorst HM, Schattenberg A, Cornelissen JJ et al. Donor lymphocyte infusions for relapsed multiple myeloma after allogencic stem-cell transplantation: predictive factors for response and long-term outcome. J Clin Oncol 2000; 18: 3013-3037.
32. Salama M, Nevill T, Marcellus D et al. Donor leukocyte infusions for multiple myeloma. Bone Marrow Transplant 2000; 26 1179-1184.
33. Bertz H, Burger JA, Kunzmann R et al. Adoptive immunotherapy for relapsed multiple myeloma after allogeneic BMT: evidence of a graft-versus-myeloma effect. Leukemia 1997; 11: 281-283.
34. Harousseau JL. Optimizing peripheral blood progenitor cell autologous transplantation in multiple myeloma. Haematology 1999; 84: 548-553.
35. Attal M, Harrousseau JL. Randomized trial experience of the Intergroupe Francophone du Myelome. Sem Hematol 2001; 38: 226-230.
36. Lemoli RM, Martinelli G, Zamagni E et al. Engraftment, clinical, and molecular follow-up of patients with multiple myeloma who were reinfused with highly purified CD34+ cells to support single or tandem high-dose chemotherapy. Blood 2000; 95: 2234-2239.
37. Schiller G, Vescio R, Freytes C et al. Transplantation of CD34+ peripheral blood progenitor cells after high-dose chemotherapy for patients with advanced multiple myeloma. Blood 1995; 86: 390-397.
38. Bellaïche L, Laredo HD, Loité F et al. Magnetic resonance appearance of monoclonal gammopathies of unknown significance and multiple myeloma. Spine 1997; 22: 2551-2557.
39. Carlson K, Astrom G, Nyman R et al. MR imaging of multiple myeloma in tumour mass measurement at diagnosis and during treatment. Acta Radiol 1995; 36: 9-14.
40. Singhal S, Mehta J, Desikan R et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341: 1565-1571.
41. Singhal S, Mehta J. Novel therapies in myeloma. Int J Hematol 2003; 77: 226-231.